Fig. 1 · Structure
Documents & Downloads
DLCI-1
Cytochrome P450 Inhibitor
DLCI-1 is a selective oral inhibitor of cytochrome P450 2A6 (CYP2A6), demonstrating potent activity in modulating nicotine metabolism. This compound has been shown to significantly reduce nicotine self-administration in both male and female murine models, making it a valuable tool for research into nicotine addiction and metabolism. Its specificity towards CYP2A6 supports investigations into the therapeutic implications of targeting this enzyme in drug development and addiction studies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2244569-14-8 |
| Applications | Cytochrome P450 Inhibitor |
| Formula | C12H14N2S |
| Molecular Weight | 218.32 |
| SMILES | NCC1=CC=C(S1)C2=C(CC)C=CN=C2 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.